Good point on mono vs addon trial. Makes me realize the risk in FREEDOM-C2 is higher but perhaps you're right and they can file based on FREEDOM-M data alone. If the drop out were really low this time, they probably have found a way to dose escalate up to 3mg, which is an efficacious dose of Remodulin, but looks like patients did not have sufficient time on that dose (Dr. Rubin's point). We both have no position but have an acquaintance with PAH.
News 
Market Data 
Discover 
AI
